Drugs / AVZO-021
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Avenzo Therapeutics, Inc. | Results Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting avenzotx.com ↗
Across all monotherapy doses, median progression-free survival (PFS) for all HR+/HER2- breast cancer patients, with a median of 4.0 (min, max: 1, 9) prior lines of therapies in the metastatic setting, was 5.3 months. |
| 2025-12-11 | Avenzo Therapeutics, Inc. | Results Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium avenzotx.com ↗
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVZO-021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998407 ↗ |
| Action | Inhibit | “AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor” NCT05867251 ↗ |
| Route | Oral | “AVZO-021 is an oral medication” NCT05867251 ↗ |
| Target | CDK2 | “AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor” NCT05867251 ↗ |